New Jersey A5062 requires health insurance and Medicaid coverage for Alzheimer's disease testing and treatments.
New Jersey A5062 mandates that health insurance and Medicaid cover diagnostic testing and FDA-approved treatments for Alzheimer's disease and related disorders. This coverage applies to various health insurance policies and contracts, including those from health maintenance organizations, medical service corporations, and health service corporations. The bill ensures that these treatments are not subject to step therapy requirements and must be provided to the same extent as for any other condition.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.